Skip to content
10-K

Annual Report

Checkmate Pharmaceuticals, Inc.

0001193125-22-088386

← back to feed
Filed
Mar 30, 2022 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2021 · Mar 29, 2022 21.63M sh
Capex FY 2021 · Dec 31, 2021 $843K
Operating Cash Flow FY 2021 · Dec 31, 2021 −$53.72M
Operating Cash Flow FY 2021 · Dec 31, 2020 −$38.11M
Short Term Investments FY 2021 · Dec 31, 2021 $20.19M
Short Term Investments FY 2021 · Dec 31, 2020 $51.83M
Cash And Equivalents FY 2021 · Dec 31, 2021 $50.68M
Cash And Equivalents FY 2021 · Dec 31, 2020 $43.06M
Stockholders Equity FY 2021 · Dec 31, 2021 $69.46M
Stockholders Equity FY 2021 · Dec 31, 2020 $125.2M
Stockholders Equity FY 2021 · Dec 31, 2019 −$97.44M
Current Liabilities FY 2021 · Dec 31, 2021 $9.38M
Current Liabilities FY 2021 · Dec 31, 2020 $7.88M
Total Liabilities FY 2021 · Dec 31, 2021 $9.38M
Total Liabilities FY 2021 · Dec 31, 2020 $7.88M
Current Assets FY 2021 · Dec 31, 2021 $73.96M
Current Assets FY 2021 · Dec 31, 2020 $102.1M
Total Assets FY 2021 · Dec 31, 2021 $78.84M
Total Assets FY 2021 · Dec 31, 2020 $133.07M
Sga Expense FY 2021 · Dec 31, 2021 $15.65M
Sga Expense FY 2021 · Dec 31, 2020 $10.19M
Rd Expense FY 2021 · Dec 31, 2021 $45.82M
Rd Expense FY 2021 · Dec 31, 2020 $26.72M
Net Income FY 2021 · Dec 31, 2021 −$61.41M
Net Income FY 2021 · Dec 31, 2020 −$36.91M
Operating Income FY 2021 · Dec 31, 2021 −$61.47M
Operating Income FY 2021 · Dec 31, 2020 −$36.9M